Absci reports interim Phase 1 data for ABS-201 in androgenetic alopecia, showing favorable safety, no serious adverse events and a half-life of at least 65 days.
Written By: Khushi Patel, PharmD
Reviewed By: Pharmacally Editorial Team
Absci reported positive interim Phase 1 findings from the first-in-human HEADLINE trial of ABS-201, an investigational antibody targeting the prolactin receptor (PRLR). The data showed a favorable safety profile across four single ascending dose cohorts and an estimated half-life of at least 65 days, supporting further evaluation of less frequent dosing in androgenetic alopecia (AGA).
Phase 1 Study Advances to Multiple-Dose Testing
The randomized, double-blind, placebo-controlled HEADLINE trial (NCT07317544) evaluated ABS-201 in healthy adults with and without AGA. Interim data from 32 participants across four single ascending dose (SAD) cohorts covered intravenous doses of 150 mg, 450 mg, 900 mg and 1,800 mg. Following review by the trial’s Safety Review Committee, Absci advanced the study into the subcutaneous multiple ascending dose (MAD) portion in participants with AGA.
No serious adverse events were reported through the June 8, 2026 data cutoff. Most treatment-emergent adverse events (TEAEs) were mild. One moderate headache occurred in the 900 mg cohort and was considered unlikely to be related to treatment. Five participants reported treatment-related TEAEs, all of which were mild, while headache was the most frequently reported TEAE across cohorts, occurring in four participants.
Long Pharmacokinetic Exposure Supports Infrequent Dosing
Interim pharmacokinetic analysis estimated ABS-201’s half-life at least 65 days, based on data across all four SAD cohorts, including Day 56 follow-up in the lower-dose groups. Absci said the exposure profile could support two or three doses over a six-month period, although continued follow-up is required to confirm the duration of exposure.
The company also reported no apparent effect of anti-drug antibodies on pharmacokinetics in the interim SAD analysis.
PRLR Targeting Under Evaluation for Hair Regrowth
ABS-201 targets prolactin receptors, with the program focused on stimulating hair follicle regeneration and promoting durable hair regrowth. Absci cited preclinical studies in which ABS-201 produced statistically significant greater hair regrowth than minoxidil in a mouse model. These findings remain preclinical and require validation in controlled clinical studies.
AGA is a common form of hair loss characterized by progressive scalp hair thinning, including crown balding and receding hairlines in men and diffuse thinning in women. The company estimates that the condition affects approximately 80 million Americans.
MAD Cohorts Will Assess Clinical Proof of Concept
The MAD portion of HEADLINE is evaluating subcutaneous ABS-201 at 300 mg, 600 mg and 1,200 mg, alongside matching placebo. The Phase 1/2a study plans to enroll up to 227 healthy adults across SAD and MAD cohorts.
Primary endpoints include safety and tolerability, while secondary measures include pharmacokinetics, pharmacodynamics, immunogenicity, target-area hair count, hair width and pigmentation, as well as patient- and investigator-reported outcomes.
Absci expects interim proof-of-concept data in the second half of 2026, followed by full proof-of-concept results in early 2027. The company is also evaluating ABS-201 for endometriosis and stated that it plans to initiate a Phase 2 study in that indication later in 2026.
The current findings are interim and primarily establish the early safety and pharmacokinetic profile of ABS-201. Whether the antibody can produce clinically meaningful and durable hair regrowth will depend on results from the ongoing MAD cohorts and subsequent development.
Reference
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR), absci, 24 September 2026
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults with and Without Androgenetic Alopecia, ClinicalTrials.gov ID NCT07317544
About the Writer
Khushi Patel is a Pharm.D (Linkedin) professional with a strong foundation in clinical pharmacy, patient-centered care, regulatory affairs, and pharmacovigilance, with published work on Brugada syndrome.
Her interests include regulatory affairs, pharmacovigilance, guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization, with a focus on evidence-based clinical decision-making and medication safety.
As a Pharmacally healthcare writer, she translates clinical and scientific evidence into clear, accurate, and clinically relevant healthcare content, while continuously developing her expertise in evolving pharmacy practice.